Pharma's Almanac TV
PA TV
Your Name
Your Email
Manage Account
Dashboard
Sign Out
Sign In
Register
Topics
Products
ADC
API - Small Molecule
Biologics
Biopharmaceuticals
Biosimilars
Cell and Gene Therapy
DNA
Drug Product
Drug Substance
Equipment
Generics
Immunotherapy
Injectables
Monoclonal Antibody
Novel Therapeutics
Oral Solid Dosage
Orphan Drugs
Parenterals
Stem Cells
Vaccine
Services
Big Data
Bioprocessing
Clinical Trials
Continuous Manufacturing
Diagnostics
Drug Delivery
Drug Development
Drug Discovery
Facility
Formulation
Innovation
Oncology
Patient Adherence
Patient Centric
Preclinical
Process Development
Quality
Regulatory
Research
Serialization
Segment
Biomanufacturing
Biotechnology
CDMO
Consulting
CRO
Engineering
Equipment
Excipients
Healthcare
Intermediates
Logistics
Manufacturing
Packaging
Supply Chain
Business
Agreement
Appointment
Business
Capacity Expansion
Collaboration
Growth
Investment
Licensing
M&A
Market Expansion
Market Intelligence
Market Prediction
New Facility
Strategic Partnership
Analytics
Research
CDMO
CRO
Excipients
Pharmaceutical Equipment
Pharmaceutical Intermediates
Supply Chain Logistics
Magazine
Current Issue
Archive
Community
Company A to Z
Content Filter
More+
Staffing
Media Kit
Membership Levels
By The Numbers
Drug Development
517 Articles Available
1
22
Can't find what you're looking for? Try our
advanced search
.
Clinical Trials
ACADIA Pharmaceuticals Announces Meets the Primary Phase 3 Endpoint in Patients with Dementia-Related Psychosis
PR-M09-19-NI-036
FDA Clearance
New Vision System for Tracking Eye Movement Gets FDA Clearance
PAO-M09-19-NI-014
Competition
Current Players Could Face Competition in the PCSK9 Space
PAO-M09-19-NI-010
Financing
Pharvaris Announces $66 Million Series B Financing to Advance the Clinical Development of an Oral Therapy for Hereditary Angioedema
PR-M09-19-NI-029
Vaccine
Pfizer Announces Positive Preliminary Results from a 2 Study of its 20-Valent Pneumococcal Conjugate Vaccine Candidate for Disease Prevention in Infants
PR-M09-19-NI-028
Cannabinoids
Leveraging Biosynthetic Expertise to Access a Wide Portfolio of Cannabinoids
PAO-NI-0919-CL-001
Zika
Batavia Biosciences to Deploy Horizon Discovery’s CHO Cell Technology to Develop Anti-Zika Biotherapeutic
PR-M09-19-NI-019
Peptide Hydrogel
Peptide Hydrogels Could Help Heal Traumatic Brain Injuries
PR-M09-19-NI-014
Clinical Data
Concert Pharmaceuticals Reports Positive CTP-543 Results from Phase 2 Alopecia Areata Trial
PR-M09-19-NI-010
CRISPR
Startup Navega Therapeutics Aims to Develop a CRISPR Treatment for Pain
PAO-M09-19-NI-008
Pain Management
Using a Scorpion Toxin to Study Pain and Inflammation
PAO-M00-19-NI-002
Clinical Trials
Soligenix Announces Positive Recommendation on its Phase 3 Clinical Trial for the Treatment of Oral Mucositis
PR-M09-19-NI-007
IND Approval
ActoBio Therapeutics™ Receives IND Green Light for New Antigen-Specific Immunotherapy Study Aimed at Improving Celiac Patients' Tolerance of Gluten
PR-M09-19-NI-006
Phase III
Lilly Announces Top-Line Phase 3 Results for Oral JAK Inhibitor Baricitinib for Moderate to Severe Atopic Dermatitis
PR-M09-19-NI-001
FDA Approval
FDA Approves New Add-on Drug to Treat Off Episodes in Adults with Parkinson’s disease
PR-M08-19-NI-090
Recovering from Cancer Treatment May Get Easier
Microbiome
Finch Therapeutics Raises $53 Million to Advance Microbiome-Based Therapies for Recurrent C. Difficile, Autism and other Disease Areas
PR-M08-19-NI-078
FDA Breakthrough
Eiger Announces FDA Breakthrough Therapy Designation for Peginterferon Lambda for Treatment of Hepatitis Delta Virus Infection
PR-M08-19-NI-071
Tumor Microenvironment
Focusing on the Tumor Microenvironment Leads to Novel Drug Targets
PAO-NI-0819-CL-002
Asthma
Asthma Patients in Europe Will Have Access to a Self-Administered Syringe
PAO-M08-19-NI-031
Smart Cell Therapies
Researchers are Investigating Smart Cell Therapies
PAO-M08-19-NI-030
Drug Approval
BioMarin Going for 2020 Approval of its Hemophilia A Gene Therapy
PAO-M08-19-NI-026
KRAS Inhibitor
Amgen Reports Further Success with New KRAS Inhibitor
PAO-M08-19-NI-025
FDA Update
Vanda Pharmaceuticals FDA Update for HETLIOZ® in the Treatment of Jet Lag Disorder
PR-M08-19-NI-064
1
22
»
